Key facts
- It has raised $2.2M; the latest was Grant ($2.0M) in Aug 2024.
- Notable investors include National Institutes of Health, Michigan Rise, Invest Detroit Ventures, Innovation Partnerships, University of Michigan — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for EVOQ Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for EVOQ Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EVOQ Therapeutics
Developer of immunotherapies designed to improve the lives of individuals fighting autoimmune diseases. The company's technology focuses on utilizing a novel, proprietary nanodisc-based therapy that delivers efficacy in multiple pre-clinical models like celiac disease, type one diabetes, lupus, pemphigus, graves, rheumatoid arthritis, and more, enabling doctors to unleash and restore the body's natural immune tolerance pathways.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2016
- Employees
- 10
- Website
- evoqtherapeutics.com/
- Ownership
- Privately Held (backing)
EVOQ Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EVOQ Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EVOQ Therapeutics in its N-PORT filings yet. We sweep new filings monthly.